These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 36034881)

  • 1. Case Report: Rhabdomyolysis secondary to vildagliptin overdose in a suicidal attempt: A case report and brief literature review.
    Tang Z; Fan X; Feng Z; Han B; Guo N
    Front Pharmacol; 2022; 13():955162. PubMed ID: 36034881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacokinetics and pharmacodynamics of vildagliptin.
    He YL
    Clin Pharmacokinet; 2012 Mar; 51(3):147-62. PubMed ID: 22339447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suicide attempt by an overdose of sitagliptin, an oral hypoglycemic agent: a case report and a review of the literature.
    Furukawa S; Kumagi T; Miyake T; Ueda T; Niiya T; Nishino K; Murakami S; Murakami M; Matsuura B; Onji M
    Endocr J; 2012; 59(4):329-33. PubMed ID: 22277726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema.
    Brown NJ; Byiers S; Carr D; Maldonado M; Warner BA
    Hypertension; 2009 Sep; 54(3):516-23. PubMed ID: 19581505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Bullous Pemphigoid With Dipeptidyl-Peptidase 4 Inhibitors in Patients With Diabetes: Estimating the Risk of the New Agents and Characterizing the Patients.
    Kridin K; Bergman R
    JAMA Dermatol; 2018 Oct; 154(10):1152-1158. PubMed ID: 30090931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dipeptidyl peptidase-4 inhibitor improves cardiac function by attenuating adverse cardiac remodelling in rats with chronic myocardial infarction.
    Inthachai T; Lekawanvijit S; Kumfu S; Apaijai N; Pongkan W; Chattipakorn SC; Chattipakorn N
    Exp Physiol; 2015 Jun; 100(6):667-79. PubMed ID: 25823534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism-based population pharmacokinetic modelling in diabetes: vildagliptin as a tight binding inhibitor and substrate of dipeptidyl peptidase IV.
    Landersdorfer CB; He YL; Jusko WJ
    Br J Clin Pharmacol; 2012 Mar; 73(3):391-401. PubMed ID: 22442826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rhabdomyolysis: a rare adverse effect of diphenhydramine overdose.
    Emadian SM; Caravati EM; Herr RD
    Am J Emerg Med; 1996 Oct; 14(6):574-6. PubMed ID: 8857809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic Dipeptidyl Peptidase-4 Controls Pharmacokinetics of Vildagliptin In Vivo.
    Asakura M; Fukami T; Nakajima M; Fujii H; Atsuda K; Itoh T; Fujiwara R
    Drug Metab Dispos; 2017 Feb; 45(2):237-245. PubMed ID: 27895112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hormonal and metabolic effects of morning or evening dosing of the dipeptidyl peptidase IV inhibitor vildagliptin in patients with type 2 diabetes.
    He YL; Valencia J; Zhang Y; Schwartz SL; Ligueros-Saylan M; Foley J; Dole WP
    Br J Clin Pharmacol; 2010 Jul; 70(1):34-42. PubMed ID: 20642545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rhabdomyolysis in Clozapine Overdose.
    Jansman FG; Crommelin HA; van Hout FJ; Meulenbelt J
    Drug Saf Case Rep; 2015 Dec; 2(1):9. PubMed ID: 27747721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rhabdomyolysis and hepatotoxicity following accidental monensin ingestion: A report of two cases.
    Zhang Z; Cui S; Zhang J
    Toxicol Ind Health; 2021 Jan; 37(1):34-37. PubMed ID: 33305694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vildagliptin-induced acute lung injury: a case report.
    Ohara N; Kaneko M; Sato K; Maruyama R; Furukawa T; Tanaka J; Kaneko K; Kamoi K
    J Med Case Rep; 2016 Aug; 10(1):225. PubMed ID: 27520566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rhabdomyolysis and acute renal failure following an ethanol and diphenhydramine overdose.
    Haas CE; Magram Y; Mishra A
    Ann Pharmacother; 2003 Apr; 37(4):538-42. PubMed ID: 12659612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dipeptidyl peptidase 4 (DPP-4) is expressed in mouse and human islets and its activity is decreased in human islets from individuals with type 2 diabetes.
    Omar BA; Liehua L; Yamada Y; Seino Y; Marchetti P; Ahrén B
    Diabetologia; 2014 Sep; 57(9):1876-83. PubMed ID: 24939431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rhabdomyolysis after lamotrigine overdose: a case report and review of the literature.
    Karaoulanis SE; Syngelakis M; Fokas K
    Ann Gen Psychiatry; 2016; 15():6. PubMed ID: 26913053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of Transient Receptor Potential Channel Vanilloid 4 by DPP-4 (Dipeptidyl Peptidase-4) Inhibitor Vildagliptin Protects Against Diabetic Endothelial Dysfunction.
    Gao P; Li L; Wei X; Wang M; Hong Y; Wu H; Shen Y; Ma T; Wei X; Zhang Q; Fang X; Wang L; Yan Z; Du GH; Zheng H; Yang G; Liu D; Zhu Z
    Hypertension; 2020 Jan; 75(1):150-162. PubMed ID: 31735085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors.
    Golightly LK; Drayna CC; McDermott MT
    Clin Pharmacokinet; 2012 Aug; 51(8):501-14. PubMed ID: 22686547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Dipeptidyl Peptidase 4 Inhibitor Use With Risk of Bullous Pemphigoid in Patients With Diabetes.
    Lee SG; Lee HJ; Yoon MS; Kim DH
    JAMA Dermatol; 2019 Feb; 155(2):172-177. PubMed ID: 30624566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dipeptidyl peptidase IV Inhibitory activity of Terminalia arjuna attributes to its cardioprotective effects in experimental diabetes: In silico, in vitro and in vivo analyses.
    Mohanty IR; Borde M; Kumar C S; Maheshwari U
    Phytomedicine; 2019 Apr; 57():158-165. PubMed ID: 30668318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.